Does Tirzepatide Affect Cancer Risk? What the Trial Safety Data and Cohort Studies Show

Tirzepatide has not been shown to raise cancer risk in people, based on the randomized trials pooled so far. A 2025 meta-analysis of 13 tirzepatide trials with 13,761 participants found no increase in overall cancer or in any specific cancer type over 26 to 72 weeks. Those trials were short and were not built to measure cancer, however, and the Zepbound label still carries a boxed warning about thyroid C-cell tumors seen in rats. The question deserves a careful answer because obesity is linked to 13 cancers and the tirzepatide label opens with a tumor warning, so this guide explains what each kind of evidence can and cannot show.

Does tirzepatide cause cancer?

The trial evidence to date does not show that tirzepatide causes cancer in people. The most direct analysis comes from Kamrul-Hasan and colleagues, who pooled 13 randomized controlled trials of tirzepatide in people with and without type 2 diabetes. Over 26 to 72 weeks, the risk ratio for any cancer was 0.78 (95% confidence interval 0.53 to 1.16), which means the tirzepatide and comparison groups had statistically similar rates. Tirzepatide also did not increase the risk of any specific cancer type, with or without diabetes.

An earlier 2024 analysis by Popovic and colleagues of 9 trials in type 2 diabetes reached the same conclusion, although its authors called the findings preliminary. A trial designed to measure weight loss over a year or so is too short to catch a cancer that takes many years to develop, so the absence of a signal is reassuring without being proof of long term safety.

What do the largest trial reviews show?

The largest review, published in Annals of Internal Medicine in 2026 by Ko and colleagues, found that GLP-1 medicines and dual agonists like tirzepatide probably have little or no effect on most obesity related cancers. The team pooled 48 randomized placebo controlled trials with 94,245 participants, and every confidence interval in Figure 2 crosses 1, so none of the four results is a clear increase or decrease. The results held for semaglutide and tirzepatide, although the trials were not designed to evaluate cancer and had short follow up.

A second pooled analysis, by Li and colleagues in Obesity (2026), included 25 randomized trials of obesity medicines and found no overall link with obesity related cancer (relative risk 1.03). A coagonist subgroup that included tirzepatide showed a relative risk of 0.43, but a single subgroup built on few events is a reason for more research rather than evidence that tirzepatide prevents cancer.

Could tirzepatide lower the risk of obesity related cancers?

Some large health record studies link GLP-1 medicines, including tirzepatide, with fewer obesity related cancers, but no trial designed for this question has tested it. The strongest, by Hsu and colleagues in Annals of Oncology (2026), matched 80,899 adults with obesity and no diabetes who started a GLP-1 medicine with 80,899 who received diet or exercise counseling, and found a lower rate of 13 obesity associated cancers in the GLP-1 group (hazard ratio 0.59) over a median of 2 years.

The lower rate held in every subgroup except Black patients, and the authors concluded that prospective trials are needed to confirm causality, since people who receive a prescription weight medicine may differ from people who receive counseling in ways that matching cannot fully remove.

Data on tirzepatide alone are thinner. In a 2025 study by Ipaye and colleagues of adults with type 2 diabetes, comparing tirzepatide with DPP-4 inhibitors across 19,682 matched pairs followed for a mean of 435 days, tirzepatide was linked to a lower rate of obesity associated cancers that did not reach statistical significance (HR 0.84; 0.69 to 1.01) and to a significantly lower rate of ovarian cancer (HR 0.31; 0.10 to 0.95), a result that rests on small numbers.

Bitar and colleagues (2026) found that therapeutic dose semaglutide or tirzepatide was linked to lower colorectal and pancreatic cancer incidence than bariatric surgery, while use at any dose showed no significant differences, which shows how sensitive these findings are to the way groups are defined.

Why does the tirzepatide label warn about thyroid tumors?

The Zepbound label carries a boxed warning because tirzepatide caused thyroid C-cell tumors in rats. According to the FDA prescribing information on DailyMed, the tumors were dose dependent and duration dependent at clinically relevant exposures. The two year rat study used doses from 0.15 to 1.5 mg/kg given twice weekly, up to roughly the exposure of the 15 mg human dose.

The same warning states that it is unknown whether tirzepatide causes these tumors, including MTC, in humans, because the human relevance of the rodent finding has not been determined. For that reason tirzepatide is contraindicated for anyone with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Our guide to tirzepatide and thyroid health covers how it applies to conditions such as hypothyroidism.

Does tirzepatide raise thyroid cancer risk in people?

Randomized trials have not shown a statistically significant increase in thyroid cancer, but they also cannot rule one out. Eisa and Barood pooled 15 randomized trials of incretin based medicines, including tirzepatide, with 84,237 participants in a 2026 meta-analysis. They counted 28 thyroid cancer events in the treatment groups and 15 in the control groups, an odds ratio of 1.52 (95% CI 0.86 to 2.68).

The authors rated the certainty of this evidence as very low because thyroid cancer is rare, and they wrote that limited follow up and imprecision prevent exclusion of a clinically relevant increase. In the tirzepatide meta-analysis by Kamrul-Hasan, calcitonin, a hormone made by thyroid C-cells, rose more on the 10 mg and 15 mg doses than on placebo, yet the included trials reported no cases of papillary thyroid carcinoma.

Should people be screened for thyroid cancer on tirzepatide?

Routine thyroid screening is not recommended for most people on tirzepatide. The Zepbound label says that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of MTC and may lead to unnecessary procedures, because calcitonin tests have low specificity and thyroid disease is common in the general population.

The label instead asks people to report possible thyroid tumor symptoms promptly:

• A lump or swelling in the neck
• Trouble swallowing (dysphagia)
• Shortness of breath (dyspnea)
• Hoarseness that does not go away

An elevated calcitonin result should be evaluated further, and the label notes that patients with MTC usually have values above 50 ng/L. Our guide to lab monitoring on tirzepatide covers which routine labs are worth tracking.

Can people with a history of cancer take tirzepatide?

Whether tirzepatide suits someone after a cancer diagnosis depends on the cancer, its treatment and overall health, so a clinician who knows the full history should decide. The one firm exclusion on the label is a personal or family history of MTC or MEN 2, while trial data for other cancers are limited because weight loss trials often excluded people with recent or active cancer.

How should cancer headlines about tirzepatide be read?

Most cancer headlines about tirzepatide draw on one of the three kinds of evidence compared in Figure 5, and a headline claiming that tirzepatide prevents or causes cancer goes beyond what any of these studies can show today.

Frequently asked questions